TBRI.F Stock Overview
Acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Therma Bright Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.019 |
| 52 Week High | CA$0.075 |
| 52 Week Low | CA$0.004 |
| Beta | 3.02 |
| 11 Month Change | -41.54% |
| 3 Month Change | -61.11% |
| 1 Year Change | 26.27% |
| 33 Year Change | -93.66% |
| 5 Year Change | n/a |
| Change since IPO | -31.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| TBRI.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.6% | 1.7% | 0.3% |
| 1Y | 26.3% | 21.4% | 31.1% |
Return vs Industry: TBRI.F exceeded the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: TBRI.F underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| TBRI.F volatility | |
|---|---|
| TBRI.F Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TBRI.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TBRI.F's weekly volatility has decreased from 77% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Rob Fia | www.thermabright.com |
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company’s products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients.
Therma Bright Inc. Fundamentals Summary
| TBRI.F fundamental statistics | |
|---|---|
| Market cap | US$7.93m |
| Earnings (TTM) | -US$1.88m |
| Revenue (TTM) | US$18.50k |
428.6x
P/S Ratio-4.2x
P/E RatioIs TBRI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBRI.F income statement (TTM) | |
|---|---|
| Revenue | CA$25.85k |
| Cost of Revenue | CA$399.00 |
| Gross Profit | CA$25.45k |
| Other Expenses | CA$2.65m |
| Earnings | -CA$2.62m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0059 |
| Gross Margin | 98.46% |
| Net Profit Margin | -10,147.92% |
| Debt/Equity Ratio | 2.6% |
How did TBRI.F perform over the long term?
See historical performance and comparison